Monoclonal antibody and blood plasma ABO blood group based therapy
against COVID-19
Abstract
In new decade new coronavirus emerged. By April 2020, there is no
accepted antiviral drug or antibody against COVID-19. COVID-19
(SARS-CoV-2) has nucleic acid sequence similarity 96% with bat
coronavirus, 79.6% SARS-CoV-1. SARS-CoV-2 and SARS-CoV-1have common
human host-cell ACE2 receptor. This similarity helps for effective
vaccine and antibody development. At Wuhan, China, convalescent plasma
therapy achieved 70% recovery results. ABO blood group susceptibility
study revealed O blood group were very low risk whereas A were at high
risk against COVID-19. ABO natural antibodies have positive effect to
slowdown COVID-19 in less hygienic environment (less developed region).
Isolation of specific antibody from EBV transformed B-lymphocyte
recovered patients is encouraged. Urgent production of potent
neutralizing antibody and vaccine is required and we identified
sensitive immunogenic amino acid segment (318-510) in S1-protein domain
that contains important and essential amino acids including cysteine,
glutamic acid and aspartic acid, which associated with ACE2 expression.